Enliven Therapeutics (NASDAQ:ELVN) Shares Up 7.9% Following Analyst Upgrade

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report)'s stock price was up 7.9% on Wednesday after HC Wainwright raised their price target on the stock from $40.00 to $48.00. HC Wainwright currently has a buy rating on the stock. Enliven Therapeutics traded as high as $20.74 and last traded at $21.20. Approximately 171,529 shares changed hands during mid-day trading, a decline of 41% from the average daily volume of 292,811 shares. The stock had previously closed at $19.65.

ELVN has been the subject of several other reports. Robert W. Baird boosted their target price on Enliven Therapeutics from $40.00 to $52.00 and gave the stock an "outperform" rating in a report on Monday, June 16th. Jones Trading dropped their price target on shares of Enliven Therapeutics from $36.00 to $27.00 and set a "buy" rating on the stock in a research report on Friday, May 16th. Finally, The Goldman Sachs Group assumed coverage on shares of Enliven Therapeutics in a research note on Monday, June 16th. They issued a "buy" rating and a $37.00 price objective for the company. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Enliven Therapeutics currently has an average rating of "Buy" and a consensus price target of $41.20.

Insider Buying and Selling

In other Enliven Therapeutics news, CEO Samuel Kintz sold 12,500 shares of the firm's stock in a transaction that occurred on Tuesday, June 17th. The stock was sold at an average price of $22.18, for a total value of $277,250.00. Following the sale, the chief executive officer owned 952,892 shares of the company's stock, valued at $21,135,144.56. This trade represents a 1.29% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Joseph P. Lyssikatos sold 12,500 shares of the company's stock in a transaction that occurred on Friday, June 20th. The stock was sold at an average price of $21.40, for a total value of $267,500.00. Following the transaction, the insider owned 965,188 shares of the company's stock, valued at approximately $20,655,023.20. This trade represents a 1.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 100,111 shares of company stock valued at $1,939,549. Insiders own 25.90% of the company's stock.

Hedge Funds Weigh In On Enliven Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. FMR LLC increased its holdings in shares of Enliven Therapeutics by 3.2% during the 4th quarter. FMR LLC now owns 6,495,871 shares of the company's stock worth $146,157,000 after purchasing an additional 199,692 shares during the period. Polar Capital Holdings Plc grew its position in Enliven Therapeutics by 267.6% during the fourth quarter. Polar Capital Holdings Plc now owns 2,389,668 shares of the company's stock worth $53,768,000 after buying an additional 1,739,668 shares in the last quarter. Vanguard Group Inc. increased its stake in Enliven Therapeutics by 2.9% during the fourth quarter. Vanguard Group Inc. now owns 1,975,655 shares of the company's stock valued at $44,452,000 after acquiring an additional 55,283 shares during the period. Janus Henderson Group PLC raised its holdings in Enliven Therapeutics by 27.9% in the 4th quarter. Janus Henderson Group PLC now owns 1,331,877 shares of the company's stock valued at $30,001,000 after acquiring an additional 290,153 shares in the last quarter. Finally, Pictet Asset Management Holding SA raised its holdings in Enliven Therapeutics by 16.3% in the 4th quarter. Pictet Asset Management Holding SA now owns 972,293 shares of the company's stock valued at $21,877,000 after acquiring an additional 135,969 shares in the last quarter. Institutional investors own 95.08% of the company's stock.

Enliven Therapeutics Stock Performance

The company has a market cap of $1.04 billion, a P/E ratio of -10.99 and a beta of 0.83. The stock has a 50-day simple moving average of $19.43 and a 200 day simple moving average of $20.40.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last issued its earnings results on Wednesday, May 14th. The company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.06). Sell-side analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.